At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 25, 2026 at 16:01 ET
Nkarta reported financial results for Q4 and full year 2025, highlighting a cash balance of $295.1 million, which is expected to fund operations into 2029. The company advanced dose escalation in its NKX019 autoimmune therapy trial to 4 billion cells per dose and plans to present initial clinical data from Ntrust-1 and Ntrust-2 at a medical conference in 2026. Net loss was $104.1 million for the year, with R&D and G&A expenses declining slightly year-over-year.
- Cash, cash equivalents, and investments totaled $295.1 million as of December 31, 2025, sufficient to fund operations into 2029.
- Net loss was $104.1 million ($1.41 per share) for full year 2025, compared to $108.8 million ($1.60 per share) in 2024.
- R&D expenses decreased to $90.4 million in 2025 from $96.7 million in 2024.
- G&A expenses were flat at $31.6 million in 2025 vs. $31.5 million in 2024.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access